GlycoMimetics (GLYC) Trading Up 5.3%
Shares of GlycoMimetics, Inc. (NASDAQ:GLYC) were up 5.3% during trading on Friday . The company traded as high as $15.07 and last traded at $14.97. Approximately 531,316 shares traded hands during trading, a decline of 42% from the average daily volume of 922,494 shares. The stock had previously closed at $14.21.
A number of analysts have commented on GLYC shares. BidaskClub raised shares of GlycoMimetics from a “sell” rating to a “hold” rating in a report on Wednesday. ValuEngine raised shares of GlycoMimetics from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Roth Capital assumed coverage on shares of GlycoMimetics in a report on Monday, October 23rd. They issued a “buy” rating and a $25.00 price target for the company. Zacks Investment Research raised shares of GlycoMimetics from a “hold” rating to a “buy” rating and set a $15.00 price target for the company in a report on Friday, October 6th. Finally, Cowen reissued a “buy” rating on shares of GlycoMimetics in a report on Wednesday. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. GlycoMimetics presently has an average rating of “Buy” and a consensus target price of $17.33.
GlycoMimetics (NASDAQ:GLYC) last posted its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.04. equities analysts anticipate that GlycoMimetics, Inc. will post -1.12 earnings per share for the current year.
A number of institutional investors and hedge funds have recently bought and sold shares of GLYC. Russell Investments Group Ltd. lifted its position in GlycoMimetics by 172.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 31,379 shares of the biotechnology company’s stock valued at $350,000 after acquiring an additional 19,859 shares in the last quarter. TD Asset Management Inc. bought a new stake in GlycoMimetics during the 2nd quarter worth about $362,000. Bank of New York Mellon Corp lifted its position in GlycoMimetics by 159.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 92,911 shares of the biotechnology company’s stock worth $1,037,000 after buying an additional 57,091 shares in the last quarter. Jennison Associates LLC bought a new stake in GlycoMimetics during the 2nd quarter worth about $17,786,000. Finally, Columbus Circle Investors bought a new stake in GlycoMimetics during the 2nd quarter worth about $1,516,000. 86.81% of the stock is currently owned by institutional investors and hedge funds.
GlycoMimetics Company Profile
GlycoMimetics, Inc is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease.
Receive News & Stock Ratings for GlycoMimetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics Inc. and related stocks with our FREE daily email newsletter.